E.E. Geduld’s Coherus Oncology CHRS Stock Holding History

E.E. Geduld’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-10,000	Closed	-$163K	–	274
2014 Q4	$163K	Buy	+10,000	New	+$141K	0.09%	152

Other funds holding CHRS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

E.E. Geduld's CHRS Position: Q1 2015 in Review

E.E. Geduld sold out of Coherus Oncology (CHRS) in Q1 2015, closing a stake of 10,000 shares — an estimated $163K sold.

E.E. Geduld first reported a position in CHRS in Q4 2014 and held it in 1 quarter. The position peaked at $163K in Q4 2014. 51 funds tracked by Wall St. Rank hold CHRS as of Q1 2015.

E.E. Geduld reported no remaining Coherus Oncology position as of Q1 2015 after selling out during the quarter.
E.E. Geduld sold 10,000 Coherus Oncology shares in Q1 2015, an estimated $163K.
E.E. Geduld first reported a position in Coherus Oncology in Q4 2014 and held it in 1 quarter.
E.E. Geduld's Coherus Oncology position peaked at $163K in Q4 2014.
51 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2015.

Based on E.E. Geduld's 13F filing for Q1 2015, filed 1 May 2015.